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a b s t r a c t
Humanity isburdenedbymalariaasmillionsare infectedwith thisdisease.Althoughadvancementshave
beenmade in the treatment ofmalaria, optimism regarding our ﬁght againstmalariamust be tempered
against the problem of drug resistance in the Plasmodium parasites causing malaria. New targets are
required to overcome the resistance problem. The enzymes of the mevalonate-independent pathway
of isoprenoid biosynthesis are targets for the development of novel antimalarial drugs. One enzyme
in this pathway, 1-deoxy-D-xylulose-5-phosphate synthase (DXS), catalyzes the conversion of 1-deoxy-
D-xylulose-5-phosphate to isopentenylpyrophosphate and dimethylallyl phosphate. We demonstrate
the use of a step deletion method to identify and eliminate the putative nuclear-encoded and transit
peptides from full length DXS to yield a truncated, active, and soluble form of Plasmodium vivax DXS,
the DXS catalytic core (DXScc).
C© 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies. Open access under CC BY-NC-ND license.. Introduction
Malaria is a devastating health problem: approximately 50% of the
orld’s population is at risk of malaria, 216 million cases of malaria
ere reported in 2010, and over 650,000 people died of malaria in
010 [1,2]. Unfortunately, the strides being made to combat malaria
ust be tempered with the growing problems of drug resistance
n the parasites that cause malaria and insecticide resistance in the
osquitoes that spread the parasites [2–5]. Malaria is caused by an
nfection by one of ﬁve species of Plasmodium protozoans, speciﬁ-
ally, P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi [6,7].
nfection by P. falciparum is dominant in Africa, while infection by P.
ivax is found throughout Asia and the Americas [6,8,9]. Because of
he high mortality rate of P. falciparum malaria [10], efforts to treat
alaria have been targeted largely against P. falciparummalaria [11].
owever, P. vivax malaria is debilitating, can be fatal, and is more
idespread and difﬁcult to treat than P. falciparummalaria. Arguably,* Corresponding author. Department of Chemistry, University of South Florida, 4202
. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA. Tel.: +1 813 974 3579; fax: +1
13 974 3203.
E-mail address:merkler@usf.edu (D.J. Merkler).
211-5463 c© 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of Europe
ttp://dx.doi.org/10.1016/j.fob.2013.01.007P. vivax malaria may be a greater burden to humanity than P. falci-
parummalaria [8,11].
Enzymes involved in type II fatty acid biosynthesis [12], isoprenoid
biosynthesis [13], hemozoin biosynthesis [14], and iron sulfur cluster
assembly [15] have been identiﬁed as potential targets for the devel-
opment of novel antimalarial drugs. Of these pathways, the enzymes
required for biosynthesis of the isoprenoidprecursors, isopentenylpy-
rophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), are
particularly attractive because theplasmodial route to IPP andDMAPP
is completely orthogonal to the mammalian biosynthetic route.
IPP and DMAPP are produced in Plasmodium from pyruvate and d-
glyceraldehyde3-phosphate (GAP) via a set of seven reactions [16,17].
In man and other mammals, IPP, DMAPP, and the isoprenoids are
produced via the canonical mevalonate-dependent pathway deﬁned
by Bloch [18], Cornforth [19], Lynen [20], and Popja´k [21] over 50
years ago. One particularly intriguing target from the mevalonate-
independentpathway (MEP) is 1-deoxy-d-xylulose-5-phosphate syn-
thase (DXS). DXS catalyzes the ﬁrst and rate-determining step ofMEP.
DXS catalyzes the condensation of pyruvate and d-glyceraldehyde-3-
phosphate to 1-deoxy-d-xylulose-5-phosphate (DXP) and CO2; this
reaction being the ﬁrst- and rate-determining step of MEP [22–24].
Production of recombinant Plasmodium DXS in Escherichia coliwould
greatly enhance drug discovery efforts aimed at this enzyme.
We report here on the use of a step wise deletion approach for the
successful production of a catalytically active and soluble form of P.an Biochemical Societies. Open access under CC BY-NC-ND license.
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Fig. 1. Schematic diagram of the nuclear-encoded bipartite pre-sequence responsible
for apicoplast targeting in Plasmodium species.vivax DXS in E. coli. This catalytically active form of P. vivax DXS does
not possess either the signaling or transit peptide and is designated
the DXS catalytic core, DXScc. P. vivax DXScc has been characterized
and compared to DXS enzymes from other organisms. We ﬁnd that
the steady-state kinetic parameters and other biochemical features
of P. vivax DXScc are consistent with data published for other DXS
proteins [25,26].
2. Materials and methods
2.1. Cloning of the P. vivax dxs gene from genomic DNA
The P. vivax dxs gene was extracted from strain Sal-
1 using the following PCR primers: forward primer, 5′-
CCTAGGATCCGATGATAATGGGAACTTCCTCT-3′ and reverse primer,
5′-ATCCAAGCTTGTTGGACACCCCTCCTTGCAG-3′. The BamHI and the
HindIII restriction sites are underlined. The PCR product was cloned
into the BamHI and HindIII restriction sites of pET21b(+) to yield the
pET21b(+)-vivax-DXS plasmid with a C-terminal His6 tag. Cloning of
the P. vivax dxs gene was conﬁrmed by DNA sequencing.
2.2. Cloning of the P. vivax dxs gene and the constructs without the
signal peptide and the transit peptide from a codon optimized gene
A synthetic, codon optimized P. vivax dxs gene with 5′-NdeI and
3′-HindIII restriction sites in a pUC57 vector was obtained from Gen-
script. The full length dxs gene was excised from pUC57 vector and
cloned into NdeI and HindIII restriction sites of pET21b(+) vector with
a C-terminal His6 tag to yield the vector SH-1. Genes that would yield
DXS proteins truncated at the N-terminus were SH-2, SH-3, SH-4, SH-
5, SH-6, SH-7, SH-8, and SH-9 (N-terminal deletion of 210, 245,
252,272,303,347,357, and395 amino acids, respectively).
These were constructed by PCR extraction from the codon optimized
P. vivax dxs gene and cloned into NdeI and XhoI restriction sites of
pET28a(+) vector with N-terminal His6 tag.
2.3. Overexpression of full length and truncated P. vivax DXS proteins
in E. coli
Both full length and truncated P. vivax DXS proteins were ex-
pressed in E. coli BL-21 B(DE3) or Rosetta B(DE3) cells. A fresh colony
of E. coli containing the appropriate plasmid was cultured at 37 ◦C
in LB broth containing 100 μg/mL ampicillin for SH-1 and 50 μg/mL
kanamycin for SH-2 to SH-9 supplemented with 0.8% glucose and
25 mM potassium phosphate at pH 7.2. The cultures were grown
for 2–3 h until the OD600 reached 0.3, then diluted 100-fold, incu-
bated at 37 ◦C until the OD600 reached 0.6, and then cooled to 25 ◦C.
Expression was induced by the addition of 0.5 mM isopropyl β-d-1-
thiogalactopyranoside (IPTG), incubated for 5–6 h with shaking, the
cells harvested by centrifugation, and the cell pellets stored at −80
◦C.
2.4. DXS and DXR puriﬁcation by Ni-NTA afﬁnity chromatography
Cellswere thawed and all the puriﬁcation stepswere performed at
4 ◦C. Cells were resuspended in the binding buffer (20mMTris pH 7.5,
500mMNaCl, 20mMimidazole, and10mMBME) supplementedwith
1 mM PMSF, 4 μg/mL leupeptin, 2 μg/mL pepstatin, sonicated, and
centrifuged at 16,000× g for 20 min. The supernatant from the cell
lysate was applied to the Ni-NTA resin (1.5 cm × 5 cm, equilibrated
with the binding buffer) at a rate of 1 mL/min and the non-bound
proteins were eluted from the column by washing with 5 column
volumes of the binding buffer followed by 20 column volumes of the
wash buffer (20mM Tris pH 7.5, 500mMNaCl, 60mM imidazole, and
10mM BME. DXS SH-1 and SH-2 were eluted using elution buffer (20
mM Tris pH 7.5, 500 mM NaCl, 250 mM imidazole, and 10 mm BME),fractions containing active protein were combined and the protein
concentrated for size exclusion chromatography. The truncated DXS
protein, DXS SH-2, will be referred to as the DXS catalytic core, DXScc.
Additional details of our experimentalmethods and thematerials can
be found in the Supplementary material .
3. Results
3.1. Expression of full length P. vivax DXS using genomic DNA
The expression of proteins from Plasmodium in E. coli has always
been difﬁcult, even more so for proteins targeted to the apicoplast.
This problem arises from the differences in codon bias between E. coli
and Plasmodium species [27,28] and from the N-terminal bipartite
targeting sequence of apicoplast proteins (Fig. 1). The enzymes of the
MEP are located in lumen of the apicoplast [29]; thus, such enzymes
from Plasmodium are difﬁcult to express in E. coli. Not surprisingly,
only two MEP enzymes from Plasmodium have been expressed in
E. coli: DXR [30] and 2-C-methyl-d-erythritol 2,4-cyclodiphosphate
synthase [31]. Both were from P. falciparum and were expressed with
the N-terminal amino acids deleted from a putative catalytic core.
None of MEP enzymes from P. vivax have been expressed in E. coli, to
date.
The open reading frame corresponding for the full length dxs gene
was isolated from P. vivax genomic DNA by PCR (Fig. S1). Expression
of full length P. vivax DXS in E. coli using the dxs gene isolated from
genomic DNA was ﬁrst performed as a proof of concept. A ﬁnal yield
of 40 μg of partially puriﬁed P. vivax DXS per liter of culture from
BL-21 cells and 80 μg per liter of culture using Rosetta B(DE3) cell
line was obtained. Full length P. vivax DXS was active and exhibited a
speciﬁc activity of 1.2 ± 0.1 μmol/min/mg.
3.2. Expression of full length P. vivax DXS using a synthetic codon
optimized dxs gene
The expression of low levels of full length, active P. vivax DXS in
E. coli using the genomic dxs gene was encouraging. A synthetic P.
vivax dxs gene codon optimized for E. coli expression was prepared
to improve upon the low expression yield. Expression yields of full
P. vivax DXScc from E. coli improved to ∼1.5 mg/L of culture when
using the codon optimized gene, but a low molecular weight protein
contaminant was always present with the full length DXS (Fig. 2). We
varied an array of experimental parameters, including induction tem-
perature, induction time, IPTG concentration, and protease inhibitor
combinations, butwere unable to eliminate the lowmolecularweight
contaminant from full length P. vivax DXS.
3.3. Expression and puriﬁcation of P. vivax DXScc
Expression of full length P. vivax DXS in E. coli using the synthetic
dxs gene was complicated by the presence low molecular weight
protein (Fig. 2). This lowmolecularweight contaminant is,most likely,
a truncated form of DXS resulting from the proteolytic removal of the
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Fig. 2. SDS–PAGE analysis of nuclear encoded full length P. vivax DXS puriﬁcation.
Molecularweightmarkers (withmolecularweight values highlighted inside the bands)
(lane 1), uninduced control (lane 2), cell lysate (lane 3), ﬂow through from afﬁnity
chromatography (lane 4), and puriﬁed full length P. vivax DXS (lane 5).
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Fig. 3. Sequence comparison of the N-terminal regions of DXS from P. berghei, P. yoeli,
P. falciparum, P. vivax, and P. knowlesi. The alignments were constructed using Clustal
W2 with the asterisk (*) indicating a fully conserved residue, the colon (:) indicating
conservation between residues of strongly similar properties, and a period (.) indicating
conservation between residues of weakly similar properties. P. fal = P. falciparum.
-terminal bipartite pre-sequence by an E. coli protease. Our solution
o this problem was to directly express the P. vivax DXScc in E. coli
y eliminating the bipartite targeting peptide from the optimized
ull length dxs gene. Bioinformatic tools to predict the signal peptide
enerally workwell and predicted a signal peptide compromising the
rst 23–30 amino acids in full length P. vivax DXS (Table 1).
The accurate prediction of the transit peptide, which serves in the
ovement of a protein into the lumenof the apicoplast, is not possible
ecause transit peptides vary considerably in length and sequence. In
ddition, the cleavage site to remove the transit peptide from the
ature protein apicoplast is not well understood. Thus, there is no
onsensus sequence for the transit peptide.
Inorder to express the soluble andactiveP. vivaxDXScc without the
ignaling and transit peptides, sequences of E. coli, Deinococcus radio-
urans, and P. vivax DXS were compared (Fig. S2). Based on sequence
imilarities between the DXS enzymes from E. coli andD. radiodurans,
e designed clones SH-7 to SH-9 to eliminate large sections of the
-terminus from full length enzyme. A similar strategy was used for
he expression of active forms of P. falciparum DXR and IspF in E. coli
30,31]. Clones SH-7, SH-8, and SH-9 yielded only microgram levels
f soluble, but inactive protein per liter of culture medium.
DXS sequences from ﬁve different species of Plasmodium species
ere aligned to better capture the nature of the transit peptide.
his comparison revealed little homology in the ﬁrst 200 N-terminal
mino acids; highlighting the difﬁculty in predicting the transit pep-
ide of P. vivax DXS. Given the paucity of guidance from the sequence
omparisons on how to best design a gene coding only for DXScc,
e generated a series of clones, each with a progressively longer N-
erminal deletion in the ﬁnal P. vivax DXS-derived protein (Fig. S3).
his step deletion approach ultimately led to clone SH-2, with an
-terminal deletion of the ﬁrst 210 amino acids. Expression of the
rotein derived from SH-2, DXScc, lead to a soluble, homogenous,
nd active enzyme in good yield when expressed in E. coli. All the
ther truncated DXS proteins discussed herein produced microgram
uantities of soluble, but inactive protein upon expression in E. coli.
An investigation of the transit peptide for the P. falciparum acyl
arrier protein showed that the transit peptide is disordered or adopts
low occupancy helix [32]. Thus, one validation of the predicted
ransit peptide sequence for P. vivax DXS comes from the calculation
f sequence entropy for residues 1–250 using DisEMBL [33]. Analysisof the sequence entropy indicated that residues from 1 to 250 are
highly disordered (Fig. S4), providing further evidence that the transit
peptide for P. vivax DXS is deﬁned within the N-terminal 250 amino
acids of the full length protein. Since the signal peptide is, most likely,
encompassed by the ﬁrst ∼25 amino acids (Table 1), we propose that
the transit peptide of full length P. vivax DXS extends from about
residue 30 to about residue 250 (Fig. 3).
Nickel afﬁnity chromatography was used as a ﬁrst step in the
puriﬁcation, followed by size exclusion chromatography (Fig. 4(A)).
Two major protein peaks were observed in the size exclusion chro-
matogram. The ﬁrst peak, representing a protein with a molecular
weight corresponding to theDXScc tetramer or highmolecularweight
aggregates, exhibits little to no DXS activity. The second peak, rep-
resenting a protein with a molecular weight of the DXScc dimer, has
relatively high DXS activity (Fig. 4(B) and (C)). The ﬁnal P. vivax DXScc
preparation, obtained using nickel afﬁnity and size-exclusion chro-
matography, was >99% pure, as judged by SDS–PAGE and Western
blot analysis (using anti-His6 antibody). The ﬁnal yield of dimeric P.
vivax DXScc was approximately 30%, yielding 1 mg/L of enzyme per
liter of E. coli culture (Table 2).
3.4. Characterization of P. vivax DXScc: pH optimum, molecular weight,
and Mg(II) stoichiometry
At saturating concentrations of pyruvate and GAP, a pH optimum
of 7–7.5 was determined for P. vivax DXScc (Fig. S5). The pH optimum
for P. vivax DXScc is comparable to the values reported for DXS from
Rhodobacter capsulatus (7.0) [34] and Agrobacterium tumefaciens (8.0)
[26].
The molecular mass of active P. vivax DXScc estimated by gel ﬁl-
tration chromatography under non-denaturing conditions was 260
kDa (Fig. S6) while the molecular weight of the enzyme estimated by
SDS–PAGE analysis was 115 kDa (Fig. 4(C)). These data suggest the
P. vivax DXScc exists as a homodimer. DXS from D. radiodurans and
R. capsulatus have been reported to exist as dimers, as well [24,34].
MALDI-MS was further used to conﬁrm the molecular weight of the
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Table 1.
Predicted cleavage site between signal and transit peptides.
Software used N-terminal sequence (cleavage site highlighted) Expected length
SignalP MIMGTSSLLLLLALIITSMHVSLNAA SGKCEV 25 amino acids
PSORT MIMGTSSLLLLLALIITSMHVSLNAASGKCE V 30 amino acids
PATS MIMGTSSLLLLLALIITSMHVSLN AASGKCEV 23 amino acids
PlasmoAP MIMGTSSLLLLLALIITSMHVSLNAA SGKCEV 25 amino acids
Table 2.
Puriﬁcation of recombinant P. vivax DXScc from E. coli.
a
Step Total protein (mg) Total units (μmol/min)
Speciﬁc activity
(units/mg) Fold puriﬁcation Yieldb (%)
Ni(II) afﬁnity
chromatography
15 122 8.1 1 100
Size-exclusion
chromatography
5.0 97 19.3 2.4 80
a We could not accurately measure the total units of DXScc activity in the E. coli cell lysate due to high levels of background NADPH oxidation activity.
b The overall yield of DXScc was approximately 30%, based on our imprecise measurements of DXScc activity in the E. coli cell lysates.
Fig. 4. The puriﬁcation of P. vivax DXScc. (A) SDS–PAGE analysis of the DXScc puriﬁca-
tion. (A) Molecular weight markers (with molecular weight values highlighted inside
the bands) (lane 1), cell lysate (lane 2), ﬂow through from afﬁnity chromatography
(lane 3), wash (lane 4), elution from the afﬁnity chromatography (lane 5), and puriﬁed
DXScc after gel ﬁltration chromatography (lane 6). (B) Western blot analysis of DXScc
using an anti-His6 antibody. Protein after gel ﬁltration chromatography (lane 1), pro-
tein after afﬁnity puriﬁcation (lane 2), and molecular weight markers (with molecular
weight values highlighted inside the bands) (lane 3). (C) Gel ﬁltration proﬁle of P. vivax
DXScc during puriﬁcation.
Fig. 5. Steady-state kinetic analysis of P. vivax DXScc for pyruvate (A) and GAP (B) at
constant, ﬁxed, and saturating concentration of the other substrate.monomeric unit. The results of MALDI-MS analysis showed peaks for
M, M/2, and 2M peak with the highest intensity observed for the M
peak (Fig. S7), and themolecularweight for theMpeak corresponding
to 103,822 Da with an accuracy of 0.1% (99 Da from the theoretical
103,921 Da).
DXS catalysis requires thiamin pyrophosphate (TPP) to transfer an
acetyl unit from pyruvate to GAP in forming DXP. TPP is observed
in the crystal structures of both E. coli DXS and D. radiodurans DXS
[24]. Like other TPP-dependent enzymes, DXS also requires a divalent
metal ion for catalysis. DXS from A. tumefaciens [26], R. capsulatus
[34], Streptomyces [35], and Mycobacterium tuberculosis [36], require
Mg(II) or Mn(II) for maximum activity.
We found that P. vivax DXScc was completely active even in the
absence of any exogenously added TPP or divalent metal ion to the
assay solutions or to any of the buffers employed during the puriﬁca-
tion of the enzyme (data not shown). These data suggest that P. vivax
DXScc binds both TPP andmetal with relatively high afﬁnity and both
were acquired from the culture medium. In order to test the activity
of DXScc in the absence of TPP and metal, the protein was dialyzed
against EDTA to remove the bound cofactors. DXScc was completely
active after exhaustive dialysis against EDTA. Incubation of the en-
zyme with acidic, saturated ammonium sulfate (pH 3.5) lead to the
complete removal of TPP, with high recovery of activity upon recon-
stitutionwith TPP (Fig. S8). However, the requiredmetal ion remained
bound to the enzyme as added Mg(II) had no effect on reconstitution
of DXScc activity.Preparationofmetal-freeDXScc proveddifﬁcult as exhaustivedial-
ysis against EDTA in pH 7.0 buffer resulted in completely active en-
zyme. Incubation of the enzyme with saturated ammonium sulfate
and 5.0 mM EDTA at pH 3.5 led to the complete loss of DXScc activity,
with only a 25% recovery of activity upon the addition of Mg(II). In-
ductively coupledplasma resonancemass spectrometry (ICP-MS)was
then used to quantify the amount of Mg(II) in DXScc. Molar ratio of
Mg(II) to DXS was found out to be 0.97 ± 0.01. These results suggest
thatMg(II)may serve both a structural and catalytic role inDXScc, that
Mg(II) is bound to DXScc with a higher afﬁnity than TPP, and that the
bound Mg(II) with another divalent metal might be achieved only by
culturing the P. vivax DXScc-expressing E. coli cells in minimal media
supplemented with a divalent metal ion of interest.
3.5. Kinetic characterization of P. vivax DXScc
Steady state kinetic parameters for pyruvate and GAP for P. vivax
DXScc were calculated using the DXS–DXR coupled assay (Fig. 5). The
steady-state kinetic parameters for DXScc were comparable to DXS
from other bacterial species [39,40,50]. The relatively small differ-
ences in the steady-state kinetic parameter for P. vivax DXScc when
compared to similar values for DXS R. capsulatus and A. tumefaciens,
may result from the different pH optima of the enzyme from these
organisms (Table 3). β-Fluoropyruvate (F-Pyr), a pyruvate analog and
a known competitive inhibitor of DXS [25]was used to further charac-
terize P. vivax DXScc. F-Pyr was competitive with respect to pyruvate
with a Ki value of 200 ± 100 μM (Fig. 6), a value lower than the Ki of
1.0 ± 0.1 mM reported for DXS from R. capsulatus [25].
In conclusion, we report here on the successful expression of a
soluble and catalytically active form of P. vivax 1-deoxy-d-xylulose-
5-phosphate synthase in E. coli. P. vivax DXScc exists as a homod-
imer, contains one-bound Mg(II) per enzyme molecule, and exhibits
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Table 3
Comparison of steady state kinetic constants for pyruvate and GAP.
Organism Pyruvate GAP Comment
Km (μM) kcat (s
−1) kcat/Km (M−1 s−1) Km (μM) kcat (s−1) kcat/Km (M−1 s−1)
P. vivax a , b 870 ± 110 9.5 ± 0.5 1.1 × 104 19 ± 4 11 ± 0.9 5.7 × 105 This study
E. coli 49 ± 8.0 2.6 ± 0.11 5.3 × 104 24 ± 1.7 2.6 ± 0.11 1.1 × 105 [37]
R. capsulatus 440 ± 50 1.9 ± 0.1 4.3 × 103 68 ± 1 1.9 ± 0.1 2.8 × 104 [25]
A. tumefaciens c 40 27 6.7 × 105 23 27 1.2 × 106 [26]
a For P. vivax DXScc, the apparent kinetic constants for pyruvate were measured by varying the initial concentration of pyruvate at 0.1 mM GAP.
b For P. vivax DXScc, the apparent kinetic constants for GAP were measured by varying the initial concentration of GAP at 4.0 mM pyruvate.
c No error analysis was reported for the kinetic constants measured for A. tumefaciens DXS.
Fig. 6. The inhibition of P. vivax DXScc by β-ﬂuoropyruvate. (A) Inhibition of P. vivax
DXS by β-ﬂuoropyruvate (F-Pyr) at constant ﬁxed concentrations of pyruvate and GAP.
(B) Double reciprocal analysis of initial velocities of DXS inhibition by F-Pyr at different
ﬁxed concentration of pyruvate. The kinetic analysis was performed at following con-
centration of F-Pyr: 0 μM (•), 150 μM (o), and 200 μM (), and the initial concentration
of GAP was ﬁxed at 0.5 mM.
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Rteady-state kinetic constants similar to other DXS enzymes. Apo-
XScc is inactive and insoluble suggesting that the bound Mg(II) has
oth a catalytic and structural role in the enzyme. We also provide
ome insight concerning the bipartite pre-sequence N-terminus to
he mature catalytic core of P. vivax DXS. While not conclusive, our
ata suggest that the bipartite pre-sequence spans from amino acid
to ∼250 in the full length protein. We propose that the ﬁrst ∼25
mino acids represent the signal peptide while amino acids ∼25 to
250 represent the transit peptide. A proposed length of∼225 amino
cids for transit peptide of P. vivaxDXS iswithin the range reported for
he transit peptides of other proteins characterized from Plasmodium
Table S1). The results presented herein will foster the development
f DXS inhibitors to treat P. vivax malaria and provide a better un-
erstanding of the mechanisms used in Plasmodium for the transit of
roteins coded in the nucleus to the lumen of the apicoplast.
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